Inhibition of restenosis by ultraviolet radiation

• US 5,053,033 A
• Filed: 10/10/1990
• Issued: 10/01/1991
• Est. Priority Date: 10/10/1990
• Status: Expired due to Fees

• Current Assignee: Michael Kasinkas
• Original Assignee: Boston Advanced Technologies, Inc. (Global Technovations, Inc.)
• Inventors: Clarke, Richard H.
• Primary Examiner(s): Pellegrino, Stephen C.
• Assistant Examiner(s): SHUMAKER, STEVEN
• Application Number:
  US07/595,033
• Time in Patent Office: 356 Days
• Field of Search: 606/2, 606/3, 606/7, 606/8, 606/10-16, 128/395-398, 219/121.6-121.62
• US Class Current: 606/3
• CPC Class Codes: A61B 2017/22002 preventing restenosis
• CPC Class Codes: A61M 25/104 used for angioplasty
• CPC Class Codes: A61N 2005/0661 ultraviolet
• CPC Class Codes: A61N 5/0601 Apparatus for use inside the body

Abstract

Restenosis following angioplasty can be inhibited by reducing the proliferation of smooth muscle cells in the blood vessel walls at an angioplasty site, and such reduction in cell proliferation can be accomplished by irradiating the angioplasty site with radiation in the ultraviolet (UV) wavelength range. The ultraviolet radiation is preferably delivered via an optical fiber or other waveguide incorporated, for example, into a percutaneous catheter. In operation, the ultraviolet radiation kills smooth muscle cells at the site, thereby reducing the risk of restenosis, while minimizing damage to surrounding tissue.

Claims

1. A method of inhibiting restenosis associated with angioplasty, the method comprising:

disposing an optical waveguide means inside a blood vessel;

locating the waveguide means adjacent to an angioplasty side within the vessel; and

irradiating the angioplasty site with UV radiation having a wavelength ranging from about 240 to about 280 nanometers via said optical means to deliver non-ablative, cytotoxic radiation to smooth muscle cells forming the blood vessel in the vicinity of the angioplasty side thereby reducing susceptibility to restenosis due to blood vessel cell proliferation.

2. The method of claim 1 wherein the step of irradiating the angioplasty site further includes irradiating with a laser radiation beam via the optical waveguide means having a wavelength of about 248 to about 268 nanometers.

3. The method of claim 1 wherein the step of disposing the waveguide means inside a blood vessel further comprises employing a catheter means to carry the waveguide means.

4. The method of claim 1 wherein the method further comprises delivering ablative radiation having sufficient energy to photodecompose blood vessel plaque via the optical waveguide means to remove plaque at the angioplasty site.

5. The method of claim 1 wherein the method further comprises disposing a second optical waveguide means inside the blood vessel for delivery of ablative laser radiation having sufficient energy to photodecompose blood vessel plaque at the angioplasty site.

6. The method of claim 1 wherein the method further comprises employing with said waveguide means an inflation means disposed within the blood vessel for dilation of said blood vessel to perform angioplasty.